A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2030

Conditions

Aromatic L-amino Acid Decarboxylase Deficiency

Interventions

GENETIC

VGN-R09b injection

Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase

All Listed Sponsors

lead

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

NCT06432140 - A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency | Biotech Hunter | Biotech Hunter